Professional Documents
Culture Documents
Treatment of Acute Ischemic Stroke
Treatment of Acute Ischemic Stroke
Address correspondence to
Dr Alejandro Rabinstein, Mayo
Clinic, Department of
Neurology, W8B, 200 First St
Treatment of Acute
SW, Rochester, MN 55905,
rabinstein.alejandro@mayo.edu. Ischemic Stroke
Relationship Disclosure:
Dr Rabinstein serves as an Alejandro A. Rabinstein, MD, FAAN
associate editor for
Neurocritical Care; on the
editorial boards of Continuum:
Lifelong Learning in Neurology, ABSTRACT
the Journal of Stroke and
Cerebrovascular Diseases, Purpose of Review: This article provides an update on the state of the art of the
Neurology, and Stroke; and on emergency treatment of acute ischemic stroke with particular emphasis on the
the scientific advisory board of alternatives for reperfusion therapy.
Portola Pharmaceuticals, Inc.
Dr Rabinstein receives research/ Recent Findings: The results of several randomized controlled trials consistently
grant support from DJO Global, and conclusively demonstrating that previously functional patients with disabling
Inc, and royalties from Elsevier, strokes from a proximal intracranial artery occlusion benefit from prompt recanaliza-
Oxford University Press, and
UpToDate, Inc. tion with mechanical thrombectomy using a retrievable stent have changed the
Unlabeled Use of landscape of acute stroke therapy. Mechanical thrombectomy within 6 hours of
Products/Investigational symptom onset should now be considered the preferred treatment for these patients
Use Disclosure:
Dr Rabinstein reports along with IV thrombolysis with recombinant tissue plasminogen activator (rtPA) within
no disclosure. the first 4.5 hours for all patients who do not have contraindications for systemic
* 2017 American Academy thrombolysis. Patients who are ineligible for IV rtPA can also benefit from mechanical
of Neurology. thrombectomy. Collateral status and time to reperfusion are the main determinants
of outcome.
Summary: Timely successful reperfusion is the most effective treatment for patients
with acute ischemic stroke. Systems of care should be optimized to maximize the
number of patients with acute ischemic stroke able to receive reperfusion therapy.
INTRODUCTION This
Over the past 2 decades, the thera- article
peutic approach to acute ischemic primarily
stroke has been deeply transformed. focuses on
Long gone is the nihilism of former reperfusion
times, now replaced by the excite- strategies
ment of proven treatment options that because
can reverse ischemia and bring back these
function to patients who were otherwise
destined to death or severe disabil-
ity. The wide adoption of IV thrombol-
ysis that began 20 years ago has recently
been followed with clear evidence
that the addition of endovascular treat-
ment with mechanical thrombectomy
can further improve outcomes in pa-
tients with severe neurologic defi-
cits from a proximal intracranial vessel
occlusion.
62
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 62
ContinuumJournal.com February 2017
63
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 63
ContinuumJournal.com February 2017
64
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 64
ContinuumJournal.com February 2017
65
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 65
ContinuumJournal.com February 2017
KEY POINTS Administration (FDA) has only ap- proved rtPA for
h IV thrombolysis with hoped that this trial will answer the
use within 3 hours of
rtPA and endovascular question whether tight glycemic control
thrombectomy with is safe and beneficial after an acute is-
a retrievable stent are chemic stroke. Fever is associated with
both solidly established worse clinical results; thus, treating fever
treatments for may be beneficial.6 The value of hypo-
appropriate candidates thermia continues to be investigated.
with acute Preventing infections (which notably
ischemic stroke. includes dysphagia assessment before
h Time to reperfusion is a any oral intake) and early recurrent
major determinant of strokes are additional priorities in the
outcome in acute care of the patient with acute stroke.
ischemic stroke.
h Randomized ACUTE REPERFUSION
placebo-controlled trials TREATMENTS
have demonstrated that There is incontrovertible evidence
IV thrombolysis with that IV thrombolysis with rtPA and
rtPA is beneficial for endovascular thrombectomy with a
patients with acute
retrievable stent improve neurologic
ischemic stroke up to
outcomes in patients with acute ische-
4.5 hours from
symptom onset.
mic stroke. Both treatments should
be administered as quickly as possi-
h Some previously cited ble after stroke onset, can be com-
contraindications for IV
bined, and are safe in appropriately
thrombolysis have been
selected candidates.
revisited, thus expanding
the pool of patients
IV thrombolysis and mechanical
who can be considered thrombectomy can produce reperfu-
good candidates for sion injury after recanalization. Re-
this treatment. perfusion injury can manifest with
hemorrhage and edema. It is more
severe when the area of established
infarction is larger. Good patient se-
lection (ie, absence of a large ischemic
core) and prompt treatment are cru-
cial to avoid this complication.
Intravenous Thrombolysis
IV thrombolysis with rtPA is proven to
be effective in improving functional
outcomes after an ischemic stroke up
to 4.5 hours after symptom onset.1,7Y9
Randomized controlled trials8,9 fol-
lowed by large observational studies
confirming the rates of recovery noted
in these trials10 and meta-analyses7
support this therapeutic indication
(Figure 3-111). The US Food and Drug
KEY POINT
h Benefit from IV
thrombolysis is much
greater in the first
90 minutes from
symptom onset.
TABLE 3-1 Indications and Contraindications for IV Recombinant Tissue Plasminogen Activator
American Heart Association American Heart Association US Food and Drug Administration
Guideline 20131 Scientific Statement 201512 (FDA) Package Insert 2015 13
Indications
Ischemic stroke within 3 months Risk increased, but degree is unclear Removedb
Arterial puncture at Risk uncertain Not listed
noncompressible site within
7 days
Previous intracranial Same Warning for recent intracranial
hemorrhage hemorrhage (contraindicated if
active intracranial hemorrhage)
Suspected subarachnoid Same Contraindicated
hemorrhage
American Heart Association American Heart Association US Food and Drug Administration
Guideline 20131 Scientific Statement 201512 (FDA) Package Insert 201513
Contraindications (continued)
Major extracranial trauma rtPA can be considered Warning for recent trauma
within 14 days
Major surgery within 14 days rtPA can be considered in carefully Warning for recent surgery
selected cases
Acute myocardial infarction Administer rtPA (stroke dose) if concurrent Not listed
within 3 months stroke and acute myocardial infarction
(MI); it is also reasonable to give rtPA
after recent MI unless it was a STEMI
involving the left anterior myocardium
Additional contraindications for
3- to 4.5-hour window
KEY POINT
h Most cases of Case 3-1
symptomatic intracerebral
A 54-year-old woman presented with the sudden onset of left-sided
hemorrhage are caused
weakness and dysarthria. Her husband promptly called 911, and the
by reperfusion injury
patient arrived by ambulance to the emergency department 15 minutes
causing hemorrhagic
after symptom onset. Her National Institutes of Health Stroke Scale (NIHSS)
transformation of an
score was 6. Noncontrast CT scan showed no hemorrhage, acute ischemic
already severe stroke.
changes, or hyperdense vessel sign. She had no contraindications for
thrombolysis. IV rtPA was started 32 minutes after symptom onset. Within
the following 2 hours, the patient improved remarkably, and the following
day she had no residual symptoms.
Comment. The benefit from IV thrombolysis for patients with acute
ischemic stroke is highly dependent on time to administration.
Administration of the bolus within 60 to 90 minutes affords maximal
chances of improvement. In order to treat patients within this short time
window, it is essential to optimize the efficiency of early evaluation, CT
scanning, and drug delivery. In the United States, stroke centers are
expected to be able to consistently administer IV rtPA within 60 minutes of
patient arrival to the emergency department.
KEY POINTS
IV rtPA often fails to recanalize proxi- both arms were treated with IV rtPA. h Six recent randomized
mal artery occlusions caused by large The results were unequivocal: patients controlled trials have
clots. These are the most disabling treated with mechanical thrombectomy conclusively proven that
strokes, and strong evidence now had high rates of reperfusion and endovascular therapy
exists that these patients should be much better functional outcomes at with mechanical
considered for endovascular therapy. 90 days. thrombectomy improves
When taken in combination, these functional outcomes in
Mechanical Thrombectomy trials demonstrated that between three patients with acute
Although endovascular recanalization and seven patients must be treated to stroke from a proximal
treatment for selected patients with help one additional patient regain func- intracranial artery
occlusion (internal
severe acute ischemic stroke has been tional independence,33 which is par-
carotid artery, M1 or M2
practiced in many centers for decades, ticularly remarkable considering the
segments) when the
the publication of several recent pos- severity of the symptoms upon pre- intervention is performed
itive trials has catapulted this therapy sentation (Case 3-2). Furthermore, within 6 hours of
to the status of evidence-based treat- since the benefit conferred by mechan- symptom onset.
ment for patients with large intracra- ical thrombectomy spanned through
h Candidates for
nial artery occlusion. Previous trials the entire range of functional outcome,
endovascular stroke
had failed to show a benefit from the number necessary to treat to therapy are patients
endovascular therapy because of reduce disability by one level on the with severe neurologic
suboptimal inclusion criteria (by not modified Rankin Scale was only 2.6. symptoms, no major
requiring proof of a proximal intracra- This benefit was confirmed across ischemic changes
nial artery occlusion before randomi- multiple subgroups (including patients on the baseline CT scan,
zation), longer time to intervention, older than 80 years and those with very good prestroke
and use of less effective reperfusion severe strokes as indicated by a base- functional status, and
devices.22Y24 Instead, the six positive line NIHSS score higher than 20).33 early presentation.
trials25Y30 shared the requirement of Mechanical thrombectomy was also h Mechanical
CT angiogram for patient screen- proven to be quite safe, with a pooled thrombectomy can be
ing (only patients with documented rate of sICH of 4.4% across all patients attempted when IV
internal carotid artery or proximal treated in the intervention arms of thrombolysis does not
middle cerebral artery occlusions could the five trials.33 Few emergency treat- result in rapid clinical
be entered into the studies), empha- ments in medicine have shown this improvement and also
sized the importance of prompt inter- in patients who are
degree of success.
ineligible for IV rtPA.
vention, and almost exclusively used The dramatic benefit observed in
retrievable stents to achieve reper- these trials relied on very high reper-
fusion, devices that have been solidly fusion rates using retrievable stents.
proven to be more effective than These devices are deployed at the
their predecessors.31,32 level of the occlusive clot, capture
The main characteristics of the ran- the clot in their mesh, and are then
domized controlled trials establishing retrieved along with the clot. Inter-
the benefit of mechanical throm- ventions in these trials were prompt
bectomy are summarized in Table 3-2. and typically performed by experi-
All of them enrolled patients with enced specialists. Delays to treatment
severe neurologic deficits and good were minimized, and consequently
prestroke functional status who pres- the times to reperfusion were rela-
ented mostly within 6 hours of symp- tively short. In fact, those trials with
tom onset (Table 3-3). Major early shorter average time to reperfusion
ischemic changes on the baseline showed the greatest clinical benefit.34
CT scan were a reason for exclusion. Some unanswered questions still
The great majority of patients in exist regarding the best application of
TABLE 3-2 Summary of the Main Trials Evaluating Mechanical Thrombectomy With
Retrievable Stents for Acute Ischemic Stroke
KEY POINTS
h Careful assessment of pedient method to quantify the extent
brain imaging is TABLE 3-3 Candidates for of early ischemic damage (Figure 3-335).36
necessary to exclude
Acute Endovascular However, the noncontrast CT scan is
Stroke Therapy not sensitive for the visualization of
a large established
infarction (core). early ischemia. One of the trials used
b Age Q18 years multiphase CT angiography to evaluate
h The optimal radiologic
method to select
b NIHSS score Q6 collateral vessels,26 and another re-
candidates for b Time from symptom onset quired a CT perfusion showing a
endovascular therapy is to groin puncture G6 hours limited infarct core and evidence of
not yet established, but b Good prestroke functional penumbra before randomization. 27
the Alberta Stroke status Furthermore, many patients in trials
Programs Early CT that did not require CT perfusion by
b ASPECTS score Q6 on baseline
Score, evaluation of protocol had this imaging before in-
CT scan
collaterals on CT clusion in the study because that was
angiography, and CT b Presence of proximal
the prevailing practice in the enrolling
perfusion or MRI intracranial artery occlusion
center.25,28 CT perfusion can provide
diffusion/perfusion are ASPECTS = Alberta Stroke Program Early
CT Score; CT = computed tomography; more reliable assessment of the is-
all available options.
NIHSS = National Institutes of Health chemic region, but its acquisition re-
Stroke Scale.
quires additional time. MRI diffusion/
perfusion is broadly considered the
most accurate method to determine
mechanical thrombectomy for pa- the ischemic core and the extent of the
tients with acute ischemic stroke. In penumbra, but this technique is less
particular, the best imaging modal- available. New software packages
ity to select patients for the inter- promise to accelerate the time re-
vention remains to be determined. quired to obtain perfusion imaging.
All trials excluded patients with an Yet, at this time, it is unclear if the
Alberta Stroke Program Early CT Score additional time needed to obtain these
(ASPECTS) lower than 6 on baseline images is justified.37 Figure 3-438 illus-
CT scan. The ASPECTS provides an ex- trates the current work flow in the
Case 3-2
A 62-year-old man without past medical history collapsed in his bathroom. The noise alerted his son,
who found his father on the ground, unable to move the right side of his body and mute. He
immediately called an ambulance. Paramedics in the field noted a blood pressure of 180/100 mm Hg
and an irregularly irregular pulse. In the emergency department, the patient had a fluctuating level of
alertness, forced left gaze deviation, a right visual field deficit, global aphasia with mutism, right
hemiplegia, and severe right hypoesthesia. His National Institutes of Health Stroke Scale (NIHSS) score
was 22. Noncontrast head CT scan showed a hyperdense left middle cerebral artery sign, but his
Alberta Stroke Program Early CT Score (ASPECTS) was 10 (Figure 3-2A). CT angiogram showed a flow
gap in the left middle cerebral artery with good collateral flow distal to it (Figure 3-2B). IV
thrombolysis was started 55 minutes after symptom onset, and the patient was taken to the angiographic
suite for endovascular therapy. Groin puncture took place 67 minutes after symptom onset. Initial
injection of contrast into the left internal carotid artery showed that this vessel was occluded at the top of
its supraclinoid segment (Figure 3-2C). Complete recanalization with full reperfusion was rapidly
achieved with mechanical thrombectomy using a retrievable stent (Figure 3-2D). The patient began
improving on the angiographic table and continued to improve overnight. By the next morning, his
NIHSS score was 3. Repeat CT scan showed a small infarction in the left lenticular nucleus (Figure 3-2E).
At 3 months, the patient had full function and no residual symptoms.
Continued on page 74
72
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 72
ContinuumJournal.com February 2017
FIGURE 3-2 Imaging of the patient in Case 3-2. A, CT scan of the brain showing hyperdensity in the left middle cerebral
artery consistent with acute thrombus (arrow). B, CT angiogram showing a focal area of left middle cerebral
artery occlusion (arrow) with good collateral flow in the vessels distal to the occlusion. C, Digital subtraction
angiogram demonstrating occlusion of the distal segment of the left internal carotid artery as well as intact collaterals
supplying the peripheral middle cerebral artery branches. D, Full recanalization and reperfusion after mechanical
thrombectomy. E, Repeat CT scan showing a small residual infarction in the left basal ganglia (arrow).
evaluation and treatment of acute is- Randomized Clinical Trial of Endovas- KEY POINT
chemic stroke. cular Treatment for Acute Ischemic h Endovascular
A growing body of evidence sug- Stroke in the Netherlands (MR CLEAN) interventions for acute
stroke should be
gests that interventions performed trial.40 It is becoming increasingly clear
performed under
under conscious sedation have better that most interventions can be safely conscious sedation
outcomes than those performed un- completed using conscious sedation. whenever possible.
der general anesthesia. This finding An appropriately powered large ran-
was first reported in retrospective domized trial will be necessary to
studies39 and subsequently confirmed conclusively determine if conscious
in a subanalysis of the Multicenter sedation should be preferred over
73
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 73
ContinuumJournal.com February 2017
FIGURE 3-4 Graphic illustrating the sequence of steps in contemporary acute stroke therapy. IV thrombolysis should be given to
all patients without contraindications within 60 minutes of their arrival to the emergency department. The use of
perfusion imaging is considered optional at this time. Ideally, the time from the qualifying scan to the groin
puncture in candidates for endovascular therapy should be shorter than 60 minutes.
CT = computed tomography; DSA = digital subtraction angiography; IV = intravenous; rtPA = recombinant tissue plasminogen activator.
Reprinted with permission from Rabinstein AA, Nat Rev Neurol.38 B 2016 Alejandro A. Rabinstein. nature.com/nrneurol/journal/v12/n2/full/nrneurol.2015.241.html.
74
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 ContinuumJournal.com February 2017 74
KEY POINTS
general anesthesia during endovascular Triage of Wake-Up and Late Presenting h Patients with wake-up
stroke therapy. Strokes Undergoing Neurointervention strokes and those with
Perhaps the main question is (DAWN),43 PerfusiOn Imaging Selec- stroke of unknown time
whether the outcomes observed in tion of Ischemic STroke Patients for of onset might benefit
the randomized trials can be repli- EndoVascular ThErapy (POSITIVE),44 from acute reperfusion
cated in daily practice. To achieve this Diffusion and Perfusion Imaging Eval- if a large infarct core can
goal, triaging mechanisms must be uation for Understanding Stroke Evo- be reliably excluded.
refined and expertise must become lution 3 (DEFUSE 3),45 and A Phase IIa h It is prudent not to
more readily available. Organization Safety Study of Intravenous Thrombol- administer IV thrombolysis
and implementation of stroke net- ysis With Alteplase in MRI-Selected in patients taking the
works around comprehensive stroke Patients (MR WITNESS)46 trials. novel oral anticoagulants
centers with 24/7 neurointerventional (dabigatran, rivaroxaban,
capability must become a priority. In Intravenous Thrombolysis apixaban, edoxaban)
turn, neurointerventional centers will in Patients Taking because readily available
have to prove compliance with strict Newer Anticoagulants tests in the emergency
department cannot
metrics of efficiency and safety. IV rtPA can be administered within quantify the degree of
3 hours of symptom onset to patients active anticoagulation.
SPECIAL SITUATIONS taking warfarin whose international
Special clinical situations remain for normalized ratio (INR) is 1.7 or less.
which the evidence is insufficient to However, no adequate safety data
determine the best course of action. with the newer anticoagulants (the
Until more definite data become avail- direct thrombin inhibitor dabigatran
able, these cases should be approached and the factor Xa inhibitors riva-
considering individual factors and what roxaban, apixaban, and edoxaban)
is known from collective experience. exist. Readily available laboratory stud-
ies cannot quantify the degree of anti-
Wake-up Strokes coagulation. Thus, it is most prudent
Patients whose neurologic deficits are to withhold thrombolysis in patients
first noticed upon their awakening taking these agents.12 However, patients
represent a particular challenge to with proximal intracranial artery occlu-
the clinician. The same applies to sion may benefit from mechanical
those with unclear time of onset (such thrombectomy.
as when the patient is aphasic and the
onset of symptoms was not witnessed). Minor and Rapidly
These situations constitute formal con- Improving Deficits
traindications for IV rtPA, but it is widely Although thrombolysis is often with-
agreed that some of these patients may held because the symptoms are
benefit from reperfusion therapy. When considered mild or patients appear
the baseline CT scan shows no evidence to be rapidly improving, several ob-
of a large established infarction, it is servational studies have shown that
likely that advanced imaging with CT up to one-third of patients who are
perfusion or MR diffusion/perfusion otherwise eligible for thrombolysis
may identify those patients who can be but do not receive it for these reasons
safely treated and can improve after are disabled at 3 months.47 Thus, one
successful recanalization (Case 3-3). must be very careful when assess-
Observational studies support this ap- ing these patients. IV rtPA might be
proach,41,42 which is currently being justified when the NIHSS score is low
tested in the DWI or CTP Assess- but the symptoms are nonetheless dis-
ment With Clinical Mismatch in the abling for the patient (eg, hemianopia
75
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 75
ContinuumJournal.com February 2017
Case 3-3
A 74-year-old woman with a history of atrial fibrillation on aspirin woke up with speech difficulties
and right-sided weakness. She was feeling well when she had gone to bed the night before. Her
husband called an ambulance, and upon arrival to the emergency department, she had a National
Institutes of Health Stroke Scale (NIHSS) score of 15. CT scan of the brain was unremarkable, but CT
angiogram showed occlusion of the left middle cerebral artery with good collateral flow (Figure 3-5A).
CT perfusion demonstrated a large mismatch between the cerebral blood flow (Figure 3-5B) and
the cerebral blood volume (Figure 3-5C) throughout the entire left middle cerebral artery territory.
Consequently, the patient was taken to the angiographic suite and underwent successful recanalization
of the left middle cerebral artery by means of a retrievable stent (Figures 3-5D and 3-5E). She experienced
great clinical improvement over the subsequent 3 days. Follow-up CT scan is shown in Figure 3-5F. At
3 months, she had regained full function.
FIGURE 3-5 Imaging of the patient in Case 3-3. A, CT angiogram showing occlusion of the left middle cerebral artery (arrow);
collateral flow distal to the occlusion was satisfactory. B, Cerebral blood flow image of the CT perfusion
disclosing hypoperfusion throughout the left middle cerebral artery distribution. C, Cerebral blood volume
image of the CT perfusion showing no definite areas of established infarction. D, Digital subtraction angiogram confirming
the presence of an occlusive/subocclusive clot in the proximal left middle cerebral artery. E, Angiographic run after full
reperfusion following treatment with a retrievable stent. F, On follow-up CT scan 24 hours later, a relatively small infarction in
comparison with the initial region of hypoperfusion in the left basal ganglia and internal capsule is seen (arrow).
Comment. Wake-up strokes and strokes of unclear time of onset are particularly problematic because
these cases were not included in the trials supporting IV thrombolysis or mechanical thrombectomy.
Yet, patients with small infarct core and large penumbra can be good candidates for acute reperfusion
therapy. This is one of the situations in which the use of penumbral imaging (CT perfusion or MR
diffusion/perfusion) can be invaluable to identify good candidates for treatment. Ongoing trials should
be able to establish the best strategy for treatment of stroke with uncertain time of onset.
76
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 76
ContinuumJournal.com February 2017
KEY POINTS
in a professional driver). Improving pontine or cerebellar infarction to be h Patients with mild or
deficits that are still disabling at the time reasonable. rapidly improving
of the neurologic evaluation may simi- strokes who present
larly warrant thrombolysis. The value of FUTURE DIRECTIONS within the time window
IV rtPA within 3 hours of symptom Current efforts are focused on increas- for IV thrombolysis and
onset in patients with mild (NIHSS ing the efficiency of systems of care and still have disabling
score of 5 or less) or rapidly improving investigating new strategies for acute symptoms at the time of
deficits is being investigated in the stroke therapy. The common objective the evaluation should
Phase IIIB, Double-Blind, Multicenter is to increase the number of patients probably be offered
Study to Evaluate the Efficacy and Safety with acute ischemic stroke who can treatment with rtPA.
of Alteplase in Patients With Mild Stroke: regain perfusion of the ischemic tissue h Although patients with
Rapidly Improving Symptoms and Neu- before infarction is established. basilar artery occlusion
rologic Deficits (PRISMS) trial.48 Mobile stroke units are rapidly were not included in the
gaining acceptance. These are special randomized controlled
Posterior Circulation Strokes ambulances equipped with a portable trials of IV thrombolysis
Randomized trials of IV thrombolysis or mechanical
CT scanner and digital technology to
thrombectomy, these
and mechanical thrombectomy (ex- enable telecommunication with a
patients should be
cept for very few patients enrolled stroke specialist. They have been shown
treated with acute
in The Contribution of Intra-arterial to allow safe initiation of IV throm- reperfusion therapies
Thrombectomy in Acute Ischemic bolysis while en route to the stroke because of their dismal
Stroke in Patients Treated With Intra- center.53 This option, although expen- prognosis if recanalization
venous Thrombolysis [THRACE] trial)30 sive, can be a very welcome solution cannot be achieved.
have been restricted to patients for some heavily populated urban com- h Mobile stroke units have
with anterior circulation strokes. Yet, munities. Dispatchers and paramedics been shown to provide
clinical experience with treating pos- must receive specific stroke education a safe way to start
terior circulation infarctions with these to optimize the efficiency and safety of thrombolysis in the
therapies exists. Basilar artery occlu- these mobile units. prehospital setting.
sions can be devastating unless recan- Ways to extend the therapeutic win-
alization is achieved. Registry data dow (beyond 4.5 hours for IV therapy
indicate that IV rtPA49 and mechanical and 6 hours for mechanical thrombec-
thrombectomy50 can result in func- tomy) are being actively investigated.
tional independence at 3 months in Using more fibrin-specific fibrinolytic
30% to 40% of cases; these rates of agents has been considered a promis-
favorable outcome are clearly greater ing option for years. Trials using
than those reported without reper- desmoteplase showed no benefit,54
fusion therapy.51 The value of endo- but tenecteplase is still being studied.55
vascular therapy for acute basilar Radiologic identification of patients
occlusion is currently being investi- with better collateral flow resulting
gated in the Basilar Artery International in persistently salvageable tissue is
Cooperation Study (BASICS).52 Even broadly considered a reasonable,
among patients who are treated with albeit still unproven, approach. Se-
reperfusion strategies, mortality re- lection of candidates using perfusion
mains high (30% to 35%).49,50 There- imaging modalities is being tested in
fore, many consider extending the ongoing trials (DAWN, DEFUSE 3, and
therapeutic window for IV thromboly- MR WITNESS).43,45,46
sis beyond 4.5 hours and for mechan- Collateral flow augmentation is an-
ical thrombectomy far beyond 6 hours other proposed strategy. In current
in patients with basilar artery occlusion practice, this is sometimes attempted
who do not have a large established with vasopressors. Evidence is restricted
77
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 77
ContinuumJournal.com February 2017
to small case series and one pilot should be given unless a solid contra-
feasibility study.56 Yet, hemodynamic indication exists.
augmentation with vasopressors can At this juncture, efforts should be
occasionally work, in particular in pa- concentrated on refining systems of
tients with proximal vessel occlusions care to allow more patients to have
who are not deemed candidates for access to reperfusion treatment. Ex-
endovascular recanalization or in panding the number of candidates for
whom the recanalization attempt was intervention will require continuous
unsuccessful. Mechanical techniques education of the community to recog-
for collateral recruitment (such as ex- nize signs of stroke, improving the
ternal counterpulsation and intraaortic initial triage of patients with stroke,
inflation devices) have been shown and speeding evaluation and treat-
feasible and safe, but their efficacy ment in the hospital. Ongoing trials
remains to be proven.57 are also evaluating the possibility of
The evolution of emergency treat- extending the therapeutic window by
ment for acute ST-segment elevation using advanced imaging modalities to
myocardial infarction can inform the identify patients in whom good collat-
future of acute stroke therapy from a erals have preserved tissue viability for
proximal artery occlusion. Fibrinolysis a longer time. Collateral augmentation
followed by endovascular therapy was strategies and ultra-early administra-
initially a common practice but was tion of neuroprotective agents may
later abandoned after randomized tri- provide additional treatment venues
als demonstrated that proceeding di- in the future.
rectly to the endovascular intervention
was a superior strategy. Once systems
REFERENCES
of care are optimized to guarantee fast
1. Jauch EC, Saver JL, Adams HP Jr, et al.
access to the angiographic suite for Guidelines for the early management of
patients with acute stroke, it will be patients with acute ischemic stroke: a
necessary to perform a trial comparing guideline for healthcare professionals from
the American Heart Association/American
IV thrombolysis followed by mechan- Stroke Association. Stroke 2013;
ical thrombectomy versus primary 44(3):870Y947. doi:10.1161/
mechanical thrombectomy for patients STR.0b013e318284056a.
with severe stroke and proven proximal 2. Donnan GA, Baron JC, Ma H, Davis SM.
artery occlusion. Penumbral selection of patients for trials of
acute stroke therapy. Lancet Neurol
2009;8(3):261Y269. doi:10.1016/
CONCLUSION S1474-4422(09)70041-9.
78
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 78
ContinuumJournal.com February 2017
6. den Hertog HM, van der Worp HB, Scale: SPAN-100. Neurology 2013;80(1):21Y28.
van Gemert HM, et al. The Paracetamol doi:10.1212/WNL.0b013e31827b1ace.
(Acetaminophen) In Stroke (PAIS) trial: a 16. Anderson CS, Robinson T, Lindley RI, et al.
multicentre, randomised, placebo-controlled, Low-dose versus standard-dose alteplase in
phase III trial. Lancet Neurol acute ischemic stroke. N Engl J Med
2009;8(5):434Y440. doi:10.1016/ 2016;374(24):2313Y2323. doi:10.1056/
S1474-4422(09)70051-1. NEJMoa1515510.
7. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. 17. Seet RC, Rabinstein AA. Symptomatic
Thrombolysis for acute ischaemic stroke. intracranial hemorrhage following
Cochrane Database Syst Rev 2014;7: intravenous thrombolysis for acute ischemic
CD000213. stroke: a critical review of case definitions.
Cerebrovasc Dis 2012;34(2):106Y114.
8. Tissue plasminogen activator for acute
doi:10.1159/000339675.
ischemic stroke. The National Institute of
Neurological Disorders and Stroke rt-PA 18. Saver JL. Hemorrhage after thrombolytic
Stroke Study Group. N Engl J Med therapy for stroke: the clinically relevant
1995;333(24):1581Y1587. doi:10.1056/ number needed to harm. Stroke
NEJM199512143332401. 2007;38(8):2279Y2283. doi:10.1161/
STROKEAHA.107.487009.
9. Hacke W, Kaste M, Bluhmki E, et al.
Thrombolysis with alteplase 3 to 4.5 hours 19. Derex L, Nighoghossian N. Intracerebral
after acute ischemic stroke. N Engl J Med haemorrhage after thrombolysis for acute
2008;359(13):1317Y1329. doi:10.1056/ ischaemic stroke: an update. J Neurol
NEJMoa0804656. Neurosurg Psychiatry 2008;79(10):
1093Y1099. doi:10.1136/jnnp.2007.133371.
10. Wahlgren N, Ahmed N, Dávalos A, et al.
20. Charidimou A, Shoamanesh A, Wilson D, et al.
Thrombolysis with alteplase for acute ischaemic
Cerebral microbleeds and postthrombolysis
stroke in the Safe Implementation of
intracerebral hemorrhage risk updated
Thrombolysis in Stroke-Monitoring Study
meta-analysis. Neurology
(SITS-MOST): an observational study. Lancet
2015;85(11):927Y924. doi:10.1212/
2007;369(9558):275Y282. doi:10.1016/
WNL.0000000000001923.
S0140-6736(07)60149-4.
21. Frontera JA, Lewin Iii JJ, Rabinstein AA, et al.
11. Emberson J, Lees KR, Lyden P, et al. Effect of Guideline for reversal of antithrombotics in
treatment delay, age, and stroke severity intracranial hemorrhage: a statement for
on the effects of intravenous thrombolysis healthcare professionals from the
with alteplase for acute ischaemic stroke: a Neurocritical Care Society and Society of
meta-analysis of individual patient data Critical Care Medicine. Neurocrit Care
from randomized trials. Lancet 2016;24(1):6Y46. doi:10.1007/
2014;384(9958):1929Y1935. doi:10.1016/ s12028-015-0222-x.
S0140-6736(14)60584-5.
22. Broderick JP, Palesch YY, Demchuk AM, et al.
12. Demaerschalk BM, Kleindorfer DO, Endovascular therapy after intravenous t-PA
Adeoye OM, et al. Scientific rationale for versus t-PA alone for stroke. N Engl J Med
the inclusion and exclusion criteria for 2013;368(10):893Y903. doi:10.1056/
intravenous alteplase in acute ischemic NEJMoa1214300.
stroke: a statement for healthcare 23. Ciccone A, Valvassori L, Nichelatti M, et al.
professionals from the American Heart Endovascular treatment for acute ischemic
Association/American Stroke Association. stroke. N Engl J Med 2013;368(10):904Y913.
Stroke 2016;47(2):581Y641. doi:10.1161/ doi:10.1056/NEJMoa1213701
STR.0000000000000086.
24. Kidwell CS, Jahan R, Gornbein J, et al. A trial
13. ACTIVASE (alteplase). Prescribing information. of imaging selection and endovascular
gene.com/download/pdf/activase_prescribing. treatment for ischemic stroke. N Engl J Med
pdf. Accessed December 1, 2016. 2013;368(10):914Y923. doi:10.1056/
14. Lansberg MG, Schrooten M, Bluhmki E, et al. NEJMoa1212793.
Treatment time-specific number needed 25. Berkhemer OA, Fransen PSS, Beumer D, et al.
to treat estimates for tissue plasminogen A randomized trial of intraarterial treatment
activator therapy in acute stroke based for acute ischemic stroke. N Engl J Med 2015;
on shifts over the entire range of the 372(1):11Y20. doi:10.1056/NEJMoa1411587.
modified Rankin Scale. Stroke 26. Goyal M, Demchuk AM, Menon BK, et al.
2009;40(6):2079Y2084. doi:10.1161/ Randomized assessment of rapid
STROKEAHA.108.540708. endovascular treatment of ischemic stroke.
15. Saposnik G, Guzik AK, Reeves M, et al. Stroke N Engl J Med 2015;372(11):1019Y1030.
prognostication using age and NIH Stroke doi:10.1056/NEJMoa1414905.
79
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 79
ContinuumJournal.com February 2017
27. Campbell BC, Mitchell PJ, Kleinig TJ, et al. 38. Rabinstein AA. Stroke in 2015: acute
Endovascular therapy for ischemic stroke endovascular recanalization therapy comes
with perfusion-imaging selection. N Engl J of age. Nat Rev Neurol 2016;12(2):67Y68.
Med 2015;372(11):1009Y1018. doi:10.1056/ doi:10.1038/nrneurol.2015.241.
NEJMoa1414792. 39. Brinjikji W, Murad MH, Rabinstein AA,
28. Saver JL, Goyal M, Bonafe A, et al. et al. Conscious sedation versus general
Stent-retriever thrombectomy after anesthesia during endovascular acute
intravenous t-PA vs. t-PA alone in stroke. ischemic stroke treatment: a systematic
N Engl Med 2015;372(24):2285Y2295. review and meta-analysis. AJNR Am J
doi:10.1056/NEJMoa1415061. Neuroradiol 2015;36(6):525Y529.
29. Jovin TG, Chamorro A, Cobo E, et al. doi:10.3174/ajnr.A4159.
Thrombectomy within 8 hours after 40. van den Berg LA, Koelman DL, Berkhemer
symptom onset in ischemic stroke. N Engl J OA, et al. Type of anesthesia and differences
Med 2015;372(24):2296Y2306. doi:10.1056/ in clinical outcome after intra-arterial
NEJMoa1503780. treatment for ischemic stroke. Stroke
30. Bracard S, Ducrocq X, Mas JL. Mechanical 2015;46(5):1257Y1262. doi:10.1161/
thrombectomy after intravenous alteplase STROKEAHA.115.008699.
versus alteplase alone after stroke (THRACE): 41. Manawadu D, Bodla S, Jarosz J, et al. A
a randomized controlled trial. Lancet Neurol case-controlled comparison of thrombolysis
2016;15(11):1138Y1147. doi:10.1016/ outcomes between wake-up and known
S1474-4422(16)30177-6. time of onset ischemic stroke patients.
31. Saver JL, Jahan R, Levy EI, et al. Solitaire flow Stroke 2013;44(8):2226Y2231. doi:10.1161/
restoration device versus the Merci Retriever STROKEAHA.111.000757.
in patients with acute ischaemic stroke 42. Thomalla G, Gerloff C. Treatment concepts
(SWIFT): a randomised, parallel-group, for wake-up stroke and stroke with
non-inferiority trial. Lancet 2012; unknown time of symptom onset. Stroke
380(9849):1241Y1249. doi:10.1016/ 2015;46(9):2707Y2713. doi:10.1161/
S0140-6736(12)61384-1. STROKEAHA.115.009701.
32. Nogueira RG, Lutsep HL, Gupta R, et al. 43. ClinicalTrials.gov. Trevo and Medical
Trevo versus Merci retrievers for Management Versus Medical Management
thrombectomy revascularisation of large Alone in Wake Up and Late Presenting
vessel occlusions in acute ischaemic stroke Strokes (DAWN). clinicaltrials.gov/ct2/show/
(TREVO 2): a randomised trial. The Lancet NCT02142283?term=NCT02142283&rank=1.
2012;380(9849):1231Y1240. doi:10.1016/ Accessed December 1, 2016.
S0140-6736(12)61299-9.
44. ClinicalTrials.gov. PerfusiOn Imaging
33. Goyal M, Menon BK, van Zwam WH, et al. Selection of Ischemic STroke Patients for
Endovascular thrombectomy after EndoVascular ThErapy (POSITIVE).
large-vessel ischaemic stroke: a clinicaltrials.gov/ct2/show/NCT01852201?term=
meta-analysis of individual patient data NCT01852201&rank=1. Accessed
from five randomised trials. Lancet December 1, 2016.
2016;387(10029):1723Y1731. doi:10.1016/
S0140-6736(16)00163-X. 45. ClinicalTrials.gov. Endovascular Therapy
Following Imaging Evaluation for
34. Grotta JC, Hacke W. Stroke neurologist’s
Ischemic Stroke 3 (DEFUSE 3). clinicaltrials.
perspective on the new endovascular trials.
gov/ct2/show/NCT02586415?term=
Stroke 2015;46(6):1447Y1452. doi:10.1161/
NCT02586415& rank=1. Accessed
STROKEAHA.115.008384.
December 1, 2016.
35. Puetz V, Dzialowski I, Hill MD, Demchuk AM.
46. ClinicalTrials.gov. A Study of Intravenous
The Alberta Stroke Program Early CT Score
Thrombolysis With Alteplase in MRI-Selected
in clinical practice: what have we learned?
Patients (MR WITNESS). clinicaltrials.gov/
Int J Stroke 2009;4(5);354Y364. doi:10.1111/
ct2/show/NCT01282242?term=NCT01282242
j.1747-4949.2009.00337.x.
&rank=1. Accessed December 1, 2016.
36. Pexman JH, Barber PA, Hill MD, et al. Use of
the Alberta Stroke Program Early CT Score 47. Khatri P, Conaway MR, Johnston KC.
(ASPECTS) for assessing CT scans in patients Ninety-day outcome rates of a prospective
with acute stroke. AJNR Am J Neuroradiol cohort of consecutive patients with mild
2001;22(8):1534Y1542. ischemic stroke. Stroke 2012;43(2):560Y562.
doi:10.1161/STROKEAHA.110.593897.
37. Campbell BC, Donnan GA, Lees KR, et al.
Endovascular stent thrombectomy: the 48. ClinicalTrials.gov. A Study of the Efficacy
new standard of care for large vessel and Safety of Activase (Alteplase) in Patients
ischaemic stroke. Lancet Neurol With Mild Stroke (PRISMS). clinicaltrials.gov/
2015;14(8):846Y854. doi:10.1016/ ct2/show/NCT02072226?term=NCT02072226&
S1474-4422(15)00140-4. rank=1. Accessed December 1, 2016.
80
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 80
ContinuumJournal.com February 2017
49. Schonewille WJ, Wijman CA, Michel P, et al. Neurol 2012;11(5):397Y404. doi:10.1016/
Treatment and outcomes of acute basilar S1474-4422(12)70057-1.
artery occlusion in the Basilar Artery
54. Albers GW, von Kummer R, Truelsen T, et al.
International Cooperation Study (BASICS):
Safety and efficacy of desmoteplase given
a prospective registry study. Lancet Neurol
3-9 h after ischaemic stroke in patients with
2009;8(8):724Y730. doi:10.1016/
occlusion or high-grade stenosis in major
S1474-4422(09)70173-5.
cerebral arteries (DIAS-3): a double-blind,
50. Singer OC, Berkefeld J, Nolte CH, et al. randomised, placebo-controlled phase
Mechanical recanalization in basilar 3 trial. Lancet Neurol 2015;14(6):575Y584.
artery occlusion: the ENDOSTROKE study. doi:10.1016/S1474-4422(15)00047-2.
Ann Neurol 2015;77(3):415Y424.
doi:10.1002/ana.24336. 55. Parsons M, Spratt N, Bivard A, et al. A
randomized trial of tenecteplase versus
51. Lindsberg PJ, Mattle HP. Therapy of basilar alteplase for acute ischemic stroke. N Engl J
artery occlusion: a systematic analysis Med 2012;366(12):1099Y1107. doi:10.1056/
comparing intra-arterial and intravenous NEJMoa1109842.
thrombolysis. Stroke 2006;37(3):922Y928.
doi:10.1161/01.STR.0000202582.29510.6b. 56. Rordorf G, Koroshetz WJ, Ezzeddine MA, et al.
A pilot study of drug-induced hypertension for
52. ClinicalTrials.gov. Basilar Artery International treatment of acute stroke. Neurology 2001;56(9):
Cooperation Study (BASICS). clinicaltrials.gov/ 1210Y1213. doi:10.1212/WNL.56.9.1210.
ct2/show/NCT01717755?term=NCT01717755&
57. Shuaib A, Bornstein NM, Diener HC, et al.
rank=1. Accessed December 1, 2016.
Partial aortic occlusion for cerebral perfusion
53. Walter S, Kostopoulos P, Haass A, et al. augmentation: safety and efficacy of
Diagnosis and treatment of patients with NeuroFlo in Acute Ischemic Stroke trial.
stroke in a mobile stroke unit versus in Stroke 2011;42(6):1680Y1690. doi:10.1161/
hospital: a randomised controlled trial. Lancet STROKEAHA.110.609933.
81
Continuum (Minneap
ContinuumJournal.com
Minn) 2017;23(1):62–81 81
ContinuumJournal.com February 2017